Novartis’ TREM2 drug fails Phase 2 ALS trial
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Novartis’ TREM2 drug fails Phase 2 ALS trial" is generating significant coverage in the Business category, with 5 articles from 5 distinct sources tracked by PULSE so far.
Outlets currently covering the story include Reuters, Fierce Biotech, Investor's Business Daily and Bloomberg.com. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 45d ago.
Quick answers
Why is "Novartis’ TREM2 drug fails Phase 2 ALS trial" trending?
Because 5 independent news sources published 5 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (5)
- Novartis halts ALS drug development after mid-stage trial failure Reuters · 45d ago
- Novartis ends ALS program after phase 2 flop, adding to R&D woes Fierce Biotech · 45d ago
- Novartis Suffers Another Setback After Stock-Rocking Failures Investor's Business Daily · 45d ago
- Novartis Experimental Drug for ALS Fails in Another Pipeline Hit Bloomberg.com · 45d ago
- Novartis’ TREM2 drug fails Phase 2 ALS trial Endpoints News · 45d ago
Topics
Related trends
Novartis CEO keeps faith in Avidity deal despite taking $1.9B hit from del-desiran fail
Novartis faces a multi-billion dollar financial hit from clinical trial setbacks yet maintains financial guidance.
Eric Dane Ignored This Early ALS Symptom Before Diagnosis
Eric Dane attempted to shake off an early ALS symptom prior to his diagnosis.
Rebecca Gayheart opens up about Eric Dane’s final moments
4 news sources are covering this Entertainment story right now — PULSE is tracking how fast it spreads.
Eric Dane Recalls Rebecca Gayheart’s 10-Word Response to His ALS Diagnosis
7 news sources are covering this Entertainment story right now — PULSE is tracking how fast it spreads.
Eric Dane Shares The ALS Symptom He Didn’t Take Seriously At First
2 news sources are covering this Entertainment story right now — PULSE is tracking how fast it spreads.
Eric Dane lists every drug he tried during ‘dark period’ in posthumous memoir
Posthumous memoir revelations and insights from Rebecca Gayheart detail the final days and struggles of Eric Dane.